Overview

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Status:
Recruiting

Trial end date:
2025-05-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to potentiate adaptive immunity to enhance the anti-tumor activity of anti-PD1 antibody by the addition of anti-CTLA4 antibody or anti-LAG3 antibody (relatlimab) given in subjects with resectable locally advanced HNSCC prior to surgical resection.

Phase:

Phase 2

Details

Lead Sponsor:

Robert Ferris

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies
Immunoglobulins
Ipilimumab
Nivolumab